Long Position on SUPN @ $26.58 on 9/28/2016 (Momentum)

Supernus Pharmaceuticals, Inc. (SUPN) is a specialty pharmaceutical company.

The firm focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States.

Its marketed products for the treatment of epilepsy include Oxtellar XR, an extended-release oxcarbazepine; and Trokendi XR, an extended-release topiramate.

The company’s product candidates comprise SPN-810, a molindone hydrochloride that is in Phase III clinical trials for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder (ADHD); and SPN-812, a viloxazine hydrochloride, which is in Phase IIb clinical trials for the treatment of ADHD. It is also developing SPN-809, a viloxazine hydrochloride as a once-daily product candidate for the treatment of depression.

The company markets its products through wholesalers and pharmaceutical distributors. Shares have formed a bullish "flag" following its recent quarterly results as well as prospects of its epilepsy drug. Higher share prices are expected for this stock.

52-Weeks Trading Range: $9.51 - $26.64

Entry Point: $26.58

Stop Loss: $25.00

Target Pirce: $29.25

Updates

10/4/2016 12:09:48 PM

SUPN closed at $23.60.

Position closed on 10/4/2016 at price of $23.60 with a -11.21% loss in 6 days.

Back to Portfolio